company background image
IIQ

INOVIQ ASX:IIQ Stock Report

Last Price

AU$0.56

Market Cap

AU$52.0m

7D

-11.7%

1Y

-48.2%

Updated

28 Sep, 2022

Data

Company Financials
IIQ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IIQ Stock Overview

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.

INOVIQ Competitors

Price History & Performance

Summary of all time highs, changes and price drops for INOVIQ
Historical stock prices
Current Share PriceAU$0.56
52 Week HighAU$1.50
52 Week LowAU$0.39
Beta0.67
1 Month Change1.80%
3 Month Change22.83%
1 Year Change-48.17%
3 Year Change-60.76%
5 Year Change135.42%
Change since IPO-21.53%

Recent News & Updates

Sep 28
INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans

INOVIQ (ASX:IIQ) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Jun 08
We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely

We're Hopeful That INOVIQ (ASX:IIQ) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

IIQAU HealthcareAU Market
7D-11.7%-4.1%-3.8%
1Y-48.2%-22.2%-12.6%

Return vs Industry: IIQ underperformed the Australian Healthcare industry which returned -20.1% over the past year.

Return vs Market: IIQ underperformed the Australian Market which returned -10.6% over the past year.

Price Volatility

Is IIQ's price volatile compared to industry and market?
IIQ volatility
IIQ Average Weekly Movement13.0%
Healthcare Industry Average Movement5.3%
Market Average Movement9.6%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market4.2%

Stable Share Price: IIQ is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IIQ's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198315Leearne Hinchhttps://www.inoviq.com

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers.

INOVIQ Fundamentals Summary

How do INOVIQ's earnings and revenue compare to its market cap?
IIQ fundamental statistics
Market CapAU$51.99m
Earnings (TTM)-AU$6.51m
Revenue (TTM)AU$2.00m

26.0x

P/S Ratio

-8.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IIQ income statement (TTM)
RevenueAU$2.00m
Cost of RevenueAU$3.09m
Gross Profit-AU$1.10m
Other ExpensesAU$5.42m
Earnings-AU$6.51m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.071
Gross Margin-54.84%
Net Profit Margin-326.20%
Debt/Equity Ratio0%

How did IIQ perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IIQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IIQ?

Other financial metrics that can be useful for relative valuation.

IIQ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue18.8x
Enterprise Value/EBITDA-5.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does IIQ's PS Ratio compare to its peers?

IIQ PS Ratio vs Peers
The above table shows the PS ratio for IIQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.5x
SLA SILK Laser Australia
1.4x6.1%AU$114.2m
MAP Microba Life Sciences
10.8x44.7%AU$50.8m
HLA Healthia
1x7.1%AU$194.5m
AHX Apiam Animal Health
0.9x8.2%AU$138.7m
IIQ INOVIQ
26xn/aAU$52.0m

Price-To-Sales vs Peers: IIQ is expensive based on its Price-To-Sales Ratio (26x) compared to the peer average (3.5x).


Price to Earnings Ratio vs Industry

How does IIQ's PE Ratio compare vs other companies in the AU Healthcare Industry?

Price-To-Sales vs Industry: IIQ is expensive based on its Price-To-Sales Ratio (26x) compared to the Australian Healthcare industry average (1.2x)


Price to Sales Ratio vs Fair Ratio

What is IIQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IIQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio26x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IIQ's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IIQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IIQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IIQ's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is INOVIQ forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


4.5%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as INOVIQ has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine INOVIQ's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • INOVIQ competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has INOVIQ performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-38.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IIQ is currently unprofitable.

Growing Profit Margin: IIQ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IIQ is unprofitable, and losses have increased over the past 5 years at a rate of 38.9% per year.

Accelerating Growth: Unable to compare IIQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IIQ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.9%).


Return on Equity

High ROE: IIQ has a negative Return on Equity (-16.3%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is INOVIQ's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IIQ's short term assets (A$17.5M) exceed its short term liabilities (A$1.8M).

Long Term Liabilities: IIQ's short term assets (A$17.5M) exceed its long term liabilities (A$690.9K).


Debt to Equity History and Analysis

Debt Level: IIQ is debt free.

Reducing Debt: IIQ had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IIQ has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IIQ has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 30.8% each year.


Discover healthy companies

Dividend

What is INOVIQ current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

INOVIQ Dividend Yield vs Market
How does INOVIQ dividend yield compare to the market?
SegmentDividend Yield
Company (INOVIQ)n/a
Market Bottom 25% (AU)2.8%
Market Top 25% (AU)7.2%
Industry Average (Healthcare)2.9%
Analyst forecast in 3 Years (INOVIQ)n/a

Notable Dividend: Unable to evaluate IIQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IIQ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IIQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IIQ's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IIQ has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Leearne Hinch

5.83yrs

Tenure

AU$867,287

Compensation

Dr. Leearne Maree Hinch, BSc., B.V.M.S., M.R.C.V.S., M.B.A. has been the Chief Executive Officer of INOVIQ Ltd (formerly known as BARD1 Life Sciences Limited) since November 7, 2016. Dr. Hinch is a biotech...


CEO Compensation Analysis

Leearne Hinch's Compensation vs INOVIQ Earnings
How has Leearne Hinch's remuneration changed compared to INOVIQ's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-AU$7m

Mar 31 2022n/an/a

-AU$9m

Dec 31 2021n/an/a

-AU$11m

Sep 30 2021n/an/a

-AU$11m

Jun 30 2021AU$867kAU$330k

-AU$11m

Mar 31 2021n/an/a

-AU$8m

Dec 31 2020n/an/a

-AU$5m

Sep 30 2020n/an/a

-AU$4m

Jun 30 2020AU$712kAU$330k

-AU$3m

Mar 31 2020n/an/a

-AU$3m

Dec 31 2019n/an/a

-AU$2m

Sep 30 2019n/an/a

-AU$2m

Jun 30 2019AU$442kAU$361k

-AU$2m

Mar 31 2019n/an/a

-AU$2m

Dec 31 2018n/an/a

-AU$2m

Sep 30 2018n/an/a

-AU$2m

Jun 30 2018AU$403kAU$359k

-AU$2m

Mar 31 2018n/an/a

-AU$2m

Dec 31 2017n/an/a

-AU$2m

Sep 30 2017n/an/a

-AU$2m

Jun 30 2017AU$255kAU$203k

-AU$3m

Compensation vs Market: Leearne's total compensation ($USD558.78K) is above average for companies of similar size in the Australian market ($USD274.98K).

Compensation vs Earnings: Leearne's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IIQ's management team is considered experienced (2.2 years average tenure).


Board Members

Experienced Board: IIQ's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

ASX:IIQ Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 May 22BuyAU$10,620Philip PowellIndividual20,000AU$0.53
06 May 22BuyAU$20,083Geoffrey CummingIndividual32,967AU$0.61
02 May 22BuyAU$29,000Philip PowellIndividual50,000AU$0.58
21 Oct 21BuyAU$43,671Philip PowellIndividual40,000AU$1.10

Ownership Breakdown

What is the ownership structure of IIQ?
Owner TypeNumber of SharesOwnership Percentage
Public Companies745,1620.8%
Private Companies2,277,0282.5%
Individual Insiders15,608,62917.0%
Institutions27,643,66030.0%
General Public45,744,22349.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 22 shareholders own 50.29% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.62%
Merchant Funds Management Pty Ltd
11,610,762A$6.6m0%20.71%
6.61%
Trust Company Funds Management Ltd.
6,086,400A$3.4m0%0.93%
6%
Merchant Group Pty Ltd, Asset Management Arm
5,523,162A$3.1m0%29.16%
4.74%
David Williams
4,359,667A$2.5m0%no data
4.42%
Irmgard Irminger-Finger
4,070,000A$2.3m0%no data
4.21%
Credit Suisse, Investment Banking and Securities Investments
3,872,548A$2.2m0%no data
1.83%
Peter Gunzburg
1,684,354A$951.7k0%no data
1.2%
Traoj Pty Ltd.
1,102,933A$623.2k0%no data
1.1%
Nathan Wagner
1,010,433A$570.9k0%no data
1.1%
Tony Walker
1,008,918A$570.0k0%no data
0.98%
David Neate
902,257A$509.8k0%no data
0.92%
Jeffrey Emmanuel
845,294A$477.6k0%no data
0.81%
Washington H. Soul Pattinson and Company Limited
745,162A$421.0k0%no data
0.76%
Russell Hancock
700,000A$395.5k0%no data
0.65%
Bronte Investments Pty Ltd
600,000A$339.0k0%no data
0.62%
Ll & P Pty Ltd
574,095A$324.4k0%no data
0.6%
Netwealth Investments Ltd.
550,788A$311.2k0%no data
0.44%
Robert Johnston
404,310A$228.4k0%no data
0.43%
Philip Powell
396,631A$224.1k21.43%no data
0.19%
Geoffrey Cumming
177,414A$100.2k22.82%no data
0.033%
Leearne Hinch
30,000A$17.0k0%no data
0.021%
Carl Stubbings
19,351A$10.9k0%no data

Company Information

INOVIQ Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: INOVIQ Ltd
  • Ticker: IIQ
  • Exchange: ASX
  • Founded: 1983
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: AU$51.991m
  • Shares outstanding: 92.02m
  • Website: https://www.inoviq.com

Number of Employees


Location

  • INOVIQ Ltd
  • 23 Normanby Road
  • Notting Hill
  • Victoria
  • 3168
  • Australia


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IIQASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJun 2016
EGQDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2016
IIQCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJun 2016
EGQ0BST (Boerse-Stuttgart)YesOrdinary SharesDEEURJun 2016

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/28 00:00
End of Day Share Price2022/09/28 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.